glp 1 drugs and crohn's disease The Potential for GLP-1s in the Treatment of GLP-1R Agonists and Their Therapeutic

Differential effects of GLP-1RAs on the risk of diverse tumor types Currently, several GLP-1RAs have been approved for the treatment of type 2 diabetes (T2DM) and/or obesity, and emerging evidence suggests that these agents may influence cancer risk

Reason #2: The medications stick around longer than you think These arent medications that clear your system overnight

"Creatine supplementation and muscle preservation during weight loss." Journal of Cachexia, Sarcopenia and Muscle , 12(2), 219-231

321 , F50F68 (2021)

Likewise, the study from Diabetes Epidemiology and Management saw a mean reduction in body mass index (BMI) of 13% at six months and 19.7% at 12 months